EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient hesitancy in perioperative clinical trial enrollment during the COVID-19 pandemic

Josue D Chirinos iD, Isabella S Turco iD, Raffaele Di Fenza iD, Stefano Gianni, Grant M Larson iD, Joseph F Swingle, Oluwaseun Akeju iD, Lorenzo Berra iD

PLOS ONE · 17.01.2023 · 18 (1) · e0279643

DOI: 10.1371/journal.pone.0279643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 17.01.2023. Verfasst von Josue D Chirinos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHLBI Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has caused tremendous disruptions to non-COVID-19 clinical research. However, there has been little investigation on how patients themselves have responded to clinical trial recruitment during the COVID-19 pandemic. To investigate the effect of the COVID-19 pandemic on rates of patient consent to enrollment into non-COVID-19 clinical trials, we carried out a cross-sectional study using data from the Nitric Oxide/Acute Kidney Injury (NO/AKI) and Minimizing ICU Neurological Dysfunction with Dexmedetomidine-Induced Sleep (MINDDS) trials. All patients eligible for the NO/AKI or MINDDS trials who came to the hospital for cardiac surgery and were approached to gain consent to enrollment were included in the current study. We defined “Before COVID-19” as the time between the start of the relevant clinical trial and the date when efforts toward that clinical trial were deescalated by the hospital due to COVID-19. We defined “During COVID-19” as the time between trial de-escalation and trial completion. 5,015 patients were screened for eligibility. 3,851 were excluded, and 1,434 were approached to gain consent to enrollment. The rate of consent to enrollment was 64% in the “Before COVID-19” group and 45% in the “During COVID-19” group (n = 1,334, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansPandemicsCross-Sectional StudiesPatientsTime Factors

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
  • Department of Sociology, Wellesley College, Wellesley, Massachusetts, United States of America.
  • Respiratory Care Services, Massachusetts General Hospital, Boston, Massachusetts, United States of America.

ORCID-Profile: Josue D Chirinos, Isabella S Turco, Raffaele Di Fenza, Grant M Larson, Oluwaseun Akeju, Lorenzo Berra

Förderung

  • NHLBI NIH HHS
  • NHLBI Division of Intramural Research

Zitieren

APA

Chirinos, J. D., Turco, I. S., Di Fenza, R., Gianni, S., Larson, G. M., Swingle, J. F., Akeju, O., & Berra, L. (2023). Patient hesitancy in perioperative clinical trial enrollment during the COVID-19 pandemic. PLOS ONE, 18(1), e0279643. https://doi.org/10.1371/journal.pone.0279643

Vancouver

Chirinos JD, Turco IS, Di Fenza R, Gianni S, Larson GM, Swingle JF, et al. Patient hesitancy in perioperative clinical trial enrollment during the COVID-19 pandemic. PLOS ONE. 2023;18(1):e0279643. doi:10.1371/journal.pone.0279643

BibTeX
@article{Chirinos2023,
  author = {Chirinos, Josue D and Turco, Isabella S and Di Fenza, Raffaele and Gianni, Stefano and Larson, Grant M and Swingle, Joseph F and Akeju, Oluwaseun and Berra, Lorenzo},
  title = {Patient hesitancy in perioperative clinical trial enrollment during the COVID-19 pandemic},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {e0279643},
  doi = {10.1371/journal.pone.0279643}
}
Kostenlos starten →